Etanercept for Psoriasis in the Pediatric Population: Experience in Nine Patients
Authors:
- 24 January 2006
- journal article
- research article
- Published by Wiley in Pediatric Dermatology
- Vol. 23 (1) , 67-71
Abstract
Abstract: Psoriasis commonly affects children and adolescents, and the need for safe, effective therapy is a special consideration in the pediatric population. In recent years, the use of targeted immunomodulatory biologic agents has been increasingly studied for the treatment of psoriasis. Of these, etanercept, a tumor necrosis factor‐α antagonist, has been approved for the treatment of psoriasis and psoriatic arthritis in adults, and while it is approved for use in juvenile rheumatoid arthritis, formal studies are needed to demonstrate its safety and efficacy for childhood psoriasis. We present our preliminary experience of treating nine pediatric patients with generalized, recalcitrant psoriasis with etanercept therapy.Keywords
This publication has 18 references indexed in Scilit:
- Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: Review of the dermatologic and rheumatologic literatureJournal of the American Academy of Dermatology, 2005
- The German etanercept registry for treatment of juvenile idiopathic arthritisAnnals of the Rheumatic Diseases, 2004
- Safety overview of new disease-modifying antirheumatic drugsRheumatic Disease Clinics of North America, 2004
- SUCCESSFUL TREATMENT OF PEDIATRIC PSORIASIS WITH INFLIXIMABPediatric Dermatology, 2004
- Immunologic Targets in PsoriasisNew England Journal of Medicine, 2003
- Etanercept as Monotherapy in Patients with PsoriasisNew England Journal of Medicine, 2003
- Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label studyAnnals of the Rheumatic Diseases, 2003
- Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trialArthritis & Rheumatism, 2003
- Recombinantly Engineered Human Proteins: Transforming the Treatment of PsoriasisClinical Immunology, 2002
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000